Sulfatide Controls Insulin Secretion by Modulation of ATP-sensitive K+-Channel Activity and Ca2+-Dependent Exocytosis in Rat Pancreatic β-Cells
- Karsten Buschard1,
- Marianne Høy2,
- Krister Bokvist2,
- Hervør L. Olsen2,
- Sten Madsbad3,
- Pam Fredman4 and
- Jesper Gromada2
- 1Bartholin Instituttet, Kommunehospitalet, Copenhagen, Denmark
- 2Laboratory of Islet Cell Physiology, Novo Nordisk, Bagsværd, Denmark
- 3Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
- 4Department of Clinical Neuroscience, Section of Neurochemistry, University of Göteborg, Mölndals Hospital, Mölndal, Sweden
Abstract
The glycosphingolipid sulfatide is present in secretory granules and at the surface of pancreatic β-cells, and antisulfatide antibodies (ASA; IgG1) are found in serum from the majority of patients with newly diagnosed type 1 diabetes. Here we demonstrate that sulfatide produced a glucose- and concentration-dependent inhibition of insulin release from isolated rat pancreatic islets. This inhibition of insulin secretion was due to activation of ATP-sensitive K+-(KATP) channels in single rat β-cells. No effect of sulfatide was observed on whole-cell Ca2+-channel activity or glucose-induced elevation of cytoplasmic Ca2+ concentration. It is interesting that sulfatide stimulated Ca2+-dependent exocytosis determined by capacitance measurements and depolarized-induced insulin secretion from islets exposed to diazoxide and high external KCl. The monoclonal sulfatide antibody Sulph I as well as ASA-positive serum reduced glucose-induced insulin secretion by inhibition of Ca2+-dependent exocytosis. Our data suggest that sulfatide is important for the control of glucose-induced insulin secretion and that both an increase and a decrease in the sulfatide content have an impact on the secretory capacity of the individual β-cells.
Footnotes
-
Address correspondence and reprint requests to Karsten Buschard, MD, Bartholin Instituttet, Kommunehospitalet, DK-1399 Copenhagen K, Denmark. E-mail: buschard{at}dadlnet.dk.
Received for publication 14 February 2001 and accepted in revised form 25 April 2002.
The current affiliation of K.Bo. and J.G. is Lilly Research Laboratories, Hamburg, Germany.
ASA, antisulfatide antibodies; [Ca2+]i, free cytoplasmic Ca2+ concentration; KATP channel, ATP-sensitive K+ channel; gal-cer, galactosylceramide.
- DIABETES














